Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 20, 2006

Primary Completion Date

August 14, 2009

Study Completion Date

August 14, 2009

Conditions
Neoplasms, Colorectal
Interventions
DRUG

Pazopanib

Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases

DRUG

FOLFOX 6

FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.

DRUG

CapeOx

CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.

Trial Locations (5)

400012

GSK Investigational Site, Pārel

500482

GSK Investigational Site, Hyderabad, Andhra Pradesh

CB2 2QQ

GSK Investigational Site, Cambridge

OX3 7LJ

GSK Investigational Site, Oxford

SM2 5PT

GSK Investigational Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY